Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2600)	9/22/2009 3:20:41 PM
From: Jibacoa	Respond to of 3722

OPTR is trying again to test the resistance from the $14 to the $15 level.<g> The stock is still above $14, up 1.96% on moderate volume just above half its ADV. bigcharts.marketwatch.com OPTR reported substantially better revenues on its 2ndQ, but the loss was larger.The EL for this Yr is around $1.50 vs. $1.24 in 2008 It has negligible LTD, but has large negative CF Last week it announced new data from its PIII in which it highlighted fidaxomicin's (OPT-80) lower CDI recurrence rates and that it reduced risk of vancomycin-resistant enterococci acquisition. The data was presented at the 49th ICAAC in Frisco. Back in April it said that it plans to file an accelerated NDA for the drug to the EMEA The stock has had a good move from its Dec L at $3.30 On July 29 it made an all time H at $15.17 <g> bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2600)	7/2/2010 5:16:22 PM
From: Jibacoa	Respond to of 3722

TTHI was up 14.28% with volume a little above its ADV. bigcharts.marketwatch.com TTHI's lead products include ELND005 for the treatment of A.D. and TT-223 for the treatment of D.M. This week it announced that the first patient had received TT-301 in its PI of the drug for R.A. TT-301 is a small molecule compound that has demonstrated efficacy in preclinical models of R.A., as well as in cases of intracerebral haemorrhage and traumatic brain injury.In pre-clinical studies,it has been shown to act by inhibiting the overproduction of inflammatory cytokines, such as IL-1Beta, TNF-Alpha. The current PI of IT-301 is just to evaluate the safety, tolerability and pharmacokinetics of the drug.<g> In previous studies in rodent models, treatment with TT-301 reduced recruitment of activated microglia, reduced cerebral edema and improved motor skills and neurocognitive outcomes. The goal of I.V. administered TT-301 is to provide a short-term treatment, that following CNS injury,can reduce destructive glial cell derived inflammatory cycles, and their long-term neurotoxic effects.<g> Back on Jan25 TTHI announced the results from a PII of its gastrin analogue, TT-223, in patients with type 2 D.M. The patients who received the highest daily dose of TT-223 for 12 weeks experienced a statistically significant reduction in HbA1c of 1.13%, 6 months after completing treatment. Patients who had received placebo treatment experienced a 0.22% HbA1c reduction 6 months post-treatment. No detectable changes in weight were observed. There were no treatment-related serious adverse events. TTHI was able to significantly trim its loss on the 3rdQ The EL for this Yr. is around $0.47 vs. $0.94 in 2009 and for 2011 a further trim on the loss to around $0.35 is expected.<g> The ACTAY is $4.08 That seems doable and with some good news, the stock could get to close some of its Dec15 DG.<g> bigcharts.marketwatch.com On Dec15 was when it announced that after nine patient deaths, it was cutting the highest doses of ELND005 on the PII that was been carried together with ELN for patients with A.D.<g> The stock isn't off from its long term DT. bigcharts.marketwatch.com Bernard